Back buying Nvidia and tech today and selling pharma-anyone paying $126 needs their head examined, after China news. Irrational behaviour-they know the threat-rushing in as big tech about to geta serious wake up call. |
Yankee sellers? |
What just happened ? What a shame ! Let's try and keep it blue for today |
 LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first biologic of its kind to offer a six-month dosing schedule, potentially improving patient adherence.
The filings are based on the positive outcomes of the SWIFT and ANCHOR phase III clinical trials. In the SWIFT trials, depemokimab demonstrated a significant reduction in exacerbation and hospitalization rates for asthma patients with type 2 inflammation when used as an add-on therapy. Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo.
Depemokimab, a monoclonal antibody targeting interleukin-5 (IL-5), represents a potential advancement in treating diseases characterized by type 2 inflammation. This inflammation, often identified by blood eosinophil count, is a common factor in many patients with severe asthma and CRSwNP, leading to exacerbations and hospitalizations.
The burden of asthma in China is significant, with an estimated 46 million adults affected, and approximately 15.5% have experienced an exacerbation requiring hospitalization in the last year. CRSwNP is also a prevalent condition, affecting up to 4% of the general population, with a substantial portion having uncontrolled disease.
The pharmaceutical company's global head of Respiratory/Immunology R&D, Kaivan Khavandi, expressed confidence in the potential of depemokimab to reduce the burden of both asthma and CRSwNP on patients and healthcare systems. |
Long overdue! |
WowAmazementGSK starting to rise from the dead |
Shocking ;-) |
They released good news and the share price went up? Something not quite right here |
Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing.
GSK and Oxford establish the GSK-Oxford Cancer Immuno
Prevention Programme to advance novel cancer research
• Collaboration unites GSK and Oxford’s complementary expertise in the science
of the immune system, vaccines and cancer biology
• GSK to invest up to £50 million in collaboration to generate key insights on how
cancer develops that could inform future development of cancer vaccines
• Programme adds to existing relationship, including the ongoing GSK-Oxford
Institute of Molecular and Computational Medicine |
GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
· If approved, the new presentation will offer a convenient administration option to healthcare professionals
· Globally, up to 1 in 3 adults will develop shingles in their lifetime
· Over 25 million people in Europe have received GSK's shingles vaccine since 2018 |
More likely a shorter, seeing as it should put any sane or serious investor off buying. |
Serial ramper ..... ;0( |
I think 2025 could be the year some of these buy and hold divi companies finally have their day in the sun.
Focus has to shift from the USA at some point and with the FT100 running at fresh record highs maybe it's slowly broadening out.
Good luck all 👍🏻 |
Topped up today.
GSK has been a terrible investment over many years.
AZN formerly the drugs division of ICI way back has been many times better.
There must be capability in this company and it is time they had their day in the sun.
My portfolio is full of shares that used to be the bluest of blue chips such as GSK DGE WPP PRU and many others.
A car crash, the collapse of these 'buy and hold forever' shares has been staggering.
All the talk of AI and even crypto, seems like madness. |
Makes an even better case .... ;0) |
PE trailing 12 months is 8.71 and next 12 months is 8.4 according to Eikon ? |
Yes, on the price-to-earnings ratio, it trades at just 21.6 – bottom of its peer group, which averages 29.1. This comprises Merck KGaA at 22.8, both Zoetis and AstraZeneca at 31, and CSL at 31.4. So, GSK looks very undervalued on that basis.
The same is true on the key price-to-book and price-to-sales ratios. On the former, GSK currently trades at 3.9 against a competitor average of 6.6. And on the latter, it is presently at 1.7 compared to a 5.2 average for its peers.
The second part of this pricing assessment examines where GSK shares should be, based on future cash flow forecasts. This discounted cash flow analysis shows the stock is 70% undervalued at its current £13.58 price.
Therefore, the fair value of the stock is technically £45.27! Market unpredictability may move it lower or higher than this. But it underlines that the stock is absolutely packed with value right now. |
Jefferies are behind the curve |
Lols, despite numerous profit upgrades from the company. Idiots |
Jefferies cuts target price to 1450p from 1525p |
patience required |
needs to break 1400 |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
